Sigma 2 Receptor Ligands for Tumor Selectivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current sigma receptor ligands lack selectivity for the σ2 receptor, which is overexpressed in tumor cells, limiting their effectiveness as anticancer agents, and the mechanism of σ2 receptor-induced cell death is not fully understood.
Innovation Solution
Development of N-substituted-9-azabicyclo[3.3.1]nonan-3α-yl carbamate analogs, including radiolabeled and fluorescent derivatives, that selectively bind to σ2 receptors, inducing caspase-dependent apoptosis in tumor cells, and their use in combination with chemotherapeutic agents to enhance cancer treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing sigma receptor ligands are used, then binding to sigma receptors is achieved, but selectivity for σ2 receptor is insufficient
Solution Approach 1:
The patent modifies specific local regions of the sigma ligand molecule by substituting hydroxyl groups with carboxylic acid groups at particular positions on the aromatic rings. This localized chemical modification enhances selectivity for σ2 receptors while preserving overall binding effectiveness, allowing the ligand to distinguish between σ1 and σ2 receptor subtypes through specific molecular interactions.
Solution Approach 2:
The patent systematically changes chemical parameters of the ligand structure, specifically the substitution pattern of hydroxyl and carboxylic acid groups on the aromatic rings. By varying the number, position, and type of these substituents, the patent optimizes both binding affinity and selectivity for σ2 receptors, demonstrating that parameter changes in molecular structure directly influence receptor subtype preference.
2Productivity
If non-selective sigma ligands are used, then general sigma receptor activity is achieved, but anticancer effectiveness is limited
Solution Approach 1:
The patent introduces carboxylic acid groups at specific positions on the aromatic rings of the sigma ligand, creating localized polar regions that enhance interaction with σ2 receptors on cancer cells. This local modification increases the ligand's ability to induce apoptosis in tumor cells while maintaining selectivity, thereby improving therapeutic efficacy without requiring complete loss of general sigma receptor activity.
3Measurement precision
If σ2 selective ligands are developed, then tumor cell targeting is improved, but mechanism understanding is incomplete
Solution Approach 1:
The patent employs comprehensive analytical methods including mass spectrometry, NMR spectroscopy, and binding assays to obtain feedback information about ligand-receptor interactions. By systematically analyzing the effects of different substitution patterns on binding affinity and selectivity, the patent builds knowledge about the mechanism by which σ2 selective ligands induce apoptosis, using experimental feedback to refine understanding of the molecular basis of tumor cell targeting.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These σ2 selective ligands demonstrate potent induction of cell death in tumor cells, activating caspase-3/7 and causing DNA fragmentation, thereby acting as effective anticancer agents and chemosensitizers, with potential for targeted cancer therapy.
Implementation Method 1
activating caspase-3/7 and causing DNA fragmentation
Data Source
AI summary
A series of N-substituted 9-azabicyclo[3.3.1]nonan-3α-yl phenylcarbamate analogs are disclosed, as well as methods of their preparation. Their affinities for sigma (σ1 and σ2) receptors are described. Two new compounds, N-(9-(4-aminobutyl)-9-azabicyclo[3.3.1]nonan-3α-yl)-N′-(2-methoxy-5-methylphenyl)carbamate and N-(9-(6-aminohexyl)-9-azabicyclo[3.3.1]nonan-3α-yl)-N′-(2-methoxy-5-methylphenyl)carbamate, are shown to have a high affinity and selectivity for σ2 versus σ1 receptors. Among the disclosed compounds are biotinylated and fluorescent analogs. These compounds can serve as probes to the σ2 receptor. In addition, some disclosed compounds can induce apoptotic cell death by both caspase-dependent and caspase-independent mechanisms, and are effective for treatment of tumors. The compounds can be used as chemotherapeutics or chemosensitizers in the treatment of a wide variety of solid tumors.